Ahrnsbrak Rebecca, Stagnitti Marie N.
From 2013 to 2018, the percentage of youths aged 12 to 17 that experienced at least one major depressive episode in the past year increased from 10.7 percent to 14.4 percent, and the percentage of adults experiencing at least one past-year major depressive episode increased from 6.7 percent to 7.2 percent. In 2018, an estimated 11.8 percent of adults aged 65 or older experienced any mental illness in the past year. Among adult females, both the percentage experiencing at least one major depressive episode in the past year and the percentage experiencing serious mental illness in the past year increased from 2013 to 2018 (8.1 percent to 9.0 percent and 4.9 percent to 5.7 percent, respectively). The percentage of Black non-Hispanic adults experiencing at least one major depressive episode in the past year also increased, from 4.6 percent in 2013 to 6.1 percent in 2018. The percentage of adults living in middle- or high-income families experiencing any mental illness in the past year increased from 16.0 percent in 2013 to 17.2 percent in 2018. Prescription antidepressants and antipsychotics are two types of drug therapies sometimes prescribed to treat mental illnesses. As more people use prescription antidepressants and antipsychotics for treatment, it is important for policymakers and researchers to understand who is receiving these medications to ensure fair and equitable access to care. This Statistical Brief presents a comparison of the total number of people in the U.S. civilian noninstitutionalized population purchasing one or more antidepressant or antipsychotic prescriptions by select sociodemographic characteristics between 2013 and 2018. Estimates are based on the 2013 Medical Expenditure Panel Survey-Household Component (MEPS-HC) and the 2018 MEPS-HC. Estimates are presented separately for antidepressants and antipsychotics. Only prescriptions obtained in an outpatient setting (retail and mail-order prescribed medicines) are included in these estimates. Prescription medicines administered in an inpatient setting or in a clinic or physician’s office are excluded. All differences between estimates discussed in the text are statistically significant at the 0.05 level unless otherwise noted.
2013年至2018年期间，过去一年中经历过至少一次重度抑郁发作的12至17岁青少年比例从10.7%增至14.4%，过去一年中经历过至少一次重度抑郁发作的成年人比例从6.7%增至7.2%。2018年，估计65岁及以上成年人中，有11.8%在过去一年中患过任何精神疾病。在成年女性中，过去一年中经历过至少一次重度抑郁发作的比例以及过去一年中患有严重精神疾病的比例在2013年至2018年期间均有所上升（分别从8.1%升至9.0%以及从4.9%升至5.7%）。过去一年中经历过至少一次重度抑郁发作的非西班牙裔黑人成年人比例也有所上升，从2013年的4.6%升至2018年的6.1%。过去一年中生活在中等或高收入家庭的成年人患任何精神疾病的比例从2013年的16.0%升至2018年的17.2%。处方抗抑郁药和抗精神病药是有时用于治疗精神疾病的两类药物疗法。随着越来越多的人使用处方抗抑郁药和抗精神病药进行治疗，政策制定者和研究人员了解谁在接受这些药物治疗以确保公平和公正地获得医疗服务非常重要。本统计简报比较了2013年至2018年期间按选定社会人口学特征划分的美国非机构化平民人口中购买一种或多种抗抑郁药或抗精神病药处方的总人数。估计数基于2013年医疗支出小组调查家庭成分（MEPS-HC）和2018年MEPS-HC。抗抑郁药和抗精神病药的估计数分别列出。这些估计数仅包括在门诊环境中获得的处方（零售和邮购处方药）。住院环境或诊所或医生办公室开具的处方药不包括在内。除非另有说明，文本中讨论的估计数之间的所有差异在0.05水平上具有统计学意义。
